A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Thomas Jefferson University
M.D. Anderson Cancer Center
Rutgers, The State University of New Jersey
Zhejiang University
Weill Medical College of Cornell University
Northwestern University
Huazhong University of Science and Technology
Mayo Clinic
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
M.D. Anderson Cancer Center
Mayo Clinic
Case Comprehensive Cancer Center
National Cancer Institute (NCI)